Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could stem cells tame brain inflammation? new study tracks Real-World results

NCT ID NCT07145502

Disease control Sponsor: Biocells Medical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 76 people with autoimmune or post-infection brain inflammation who are receiving stem cell or exosome treatments. Researchers will track changes in symptoms, inflammation markers, and quality of life. The goal is to see if these experimental therapies can help when standard treatments have failed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stem cells and exosomes
What this could lead to
If successful, this could point toward a new way to manage hard-to-treat brain inflammation conditions like autoimmune encephalitis.
What could go wrong
This is an early observational study with no control group, so results may not prove the treatment works. Risks include reactions to the infusions and uncertainty about long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

76 people

The number who actually took part.

Started

Sep 2022

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include pediatric, adult, and older adult patients aged 6 to 70 years who present with clinically confirmed or strongly suspected neuroinflammatory conditions of autoimmune or post-infectious origin. These include but are not limited to autoimmune encephalitis, post-viral encephalopathies (e.g., following measles, CMV, EBV, SARS-CoV-2), early-stage panencephalitis, and chronic neuroimmune syndromes such as ME/CFS and long COVID with CNS involvement. Patients are eligible for inclusion if they have a persistent neuroinflammatory or neurocognitive condition that has not responded adequately to standard therapies or has relapsed. Diagnostic confirmation may include MRI findings, CSF analysis, neuropsychological testing, and immunological profiling (e.g., autoantibodies, cytokines).

Ages

6 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Age 6-70 * Diagnosis of one of the eligible syndromes by neurologist or immunologist * Unresponsive or partially responsive to conventional therapy * Informed consent provided Exclusion Criteria: * • Active malignancy * Severe systemic infection * Contraindications to IV biologics

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune encephalitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system autoimmune encephalitis demyelinating disease of central nervous system

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune encephalitis Early-stage panencephalitis Neuroinflammatory demyelination

Contacts and locations

Locations

  • Biocells Medical

    Warsaw, 01-234, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.